Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers
Phase 1
Terminated
- Conditions
- COVID-19 ImmunisationProtection Against COVID-19 and Infections With SARS-CoV- 2COVID-19
- Interventions
- Biological: COVID-eVaxDevice: Cliniporator® and EPSGun
- First Posted Date
- 2021-03-09
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Takis
- Target Recruit Count
- 68
- Registration Number
- NCT04788459
- Locations
- 🇮🇹
San Gerardo Hospital, Monza, Italy
🇮🇹Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Naples, Italy
🇮🇹- CRC Centro Ricerche Cliniche di Verona, Verona, Italy
© Copyright 2025. All Rights Reserved by MedPath